Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136875/?tool=EBI

Similar Items

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis
Published: (2014-01-01)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis.
Published: (2014-01-01)

Correction: Potential Formula for the Calculation of Starting and Incremental Insulin Glargine Doses: ALOHA Subanalysis.
Published: (2014-01-01)

Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis.
by: Takashi Kadowaki, et al.
Published: (2012-01-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
by: Tarigan TJE, et al.
Published: (2021-01-01)

Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)

Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis
by: Christian C.K. Kim, MD, et al.
Published: (2016-01-01)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
by: Jakobsen Marie, et al.
Published: (2012-09-01)

Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration
by: Samantha Walczuk, et al.
Published: (2024-03-01)

Analytical Model of ALOHA and Time- and Frequency-Asynchronous ALOHA with Forward Error Correction for IoT Systems
by: Federico Clazzer, et al.
Published: (2022-05-01)

Insulin Glargine Dosing Every 16 Hours for a Complicated Type I Diabetes Case
by: Khaled A. Alswat, MBBS, CCD, FACP, et al.
Published: (2016-01-01)

Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
by: Vadim Valer'evich Klimontov, et al.
Published: (2014-12-01)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
by: Mamatha Garige, et al.
Published: (2023-03-01)

Goodbye, ALOHA!
by: Andres Laya, et al.
Published: (2016-01-01)

Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
by: Kerry Mansell, et al.
Published: (2019-12-01)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
by: I. N. Dyakov, et al.
Published: (2020-09-01)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
by: Thomann R, et al.
Published: (2020-07-01)

In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
by: Mark R Sommerfeld, et al.
Published: (2010-01-01)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
by: Sondra Davis, et al.
Published: (2017-04-01)

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling
by: Xiaoli Sheng, et al.
Published: (2019-08-01)

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine
by: E Warren, et al.
Published: (2004-11-01)

Insulin glargine in the treatment of type 1 and type 2 diabetes 59
by: Anthony H Barnett
Published: (2006-03-01)

Effect of insulin glargine on glycemic control in adolescents with type 1-diabetes
by: Hassan M. Mona, et al.
Published: (2015-06-01)

Hypersensitivity reaction associated with subcutaneous glargine insulin therapy in a cat
by: Lisa A Murphy, et al.
Published: (2016-11-01)

Analytical calculation of throughput of ALOHA based protocols in optical wireless data networks
by: Samaras, K, et al.
Published: (2000)

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
by: Victor Enrique Sarmiento-Ortega, et al.
Published: (2023-04-01)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
by: Kai‐Jen Tien, et al.
Published: (2019-05-01)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
by: Yiya Wang, et al.
Published: (2022-08-01)

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
by: Sinha B, et al.
Published: (2014-06-01)

Fasting plasma glucose level-based formula for estimating starting daily dose in basal-bolus insulin therapy
by: Mototsugu Nagao, et al.
Published: (2023-01-01)

rDNA insulin glargine U300 – a critical appraisal
by: Wang F, et al.
Published: (2016-12-01)

Insulin glargine use and breast cancer: a systematic review and meta-analysis
by: Ibrahim Altedlawi Albalawi, et al.
Published: (2019-03-01)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
by: Kitty Poon, et al.
Published: (2010-10-01)

Stability Analysis of Hybrid ALOHA
by: Huahui Wang, et al.
Published: (2010-01-01)

Stability Analysis of Hybrid ALOHA
by: Wang Huahui, et al.
Published: (2010-01-01)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
by: Tetlow Anthony P, et al.
Published: (2009-01-01)

Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy
by: Pešić Milica, et al.
Published: (2007-01-01)

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
by: Mizuho Yamabe
Published: (2019-11-01)